Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Flags with the Danish Danish Novo Nordisk logo, Diabetes Blockbuster and Wegovy Wegovy Diabetes Manufacturers, while the company presents an annual report in Novo Nordisk in Bagsvaerd, Denmark, February 5, 2025.
Mads Claus Rasmussen | AFP | Gets the image
Novo nordisk On Wednesday, the higher growth of net profit was reported in the first quarter, but reduced the sales growth forecast for the full year when copy drugs impressed the demand for their blockbuster Wegovy Wegovy.
The pure profit of the Danish pharmaceutical giant amounted to 29.03 billion Danish crane ($ 4.4 billion) over the three -month period by the end of March, ahead of 27.8 billion Danish forecasts of Kronen analysts in the LSEG poll.
Novo Nordisk shares rose 4.25% to 8:38 am in London.
Sales of popular Wegovy drug drugs increased by 83% annually with permanent courses to 17.36 billion Danish crafers, just below 18.51 billion Danish crafers that analytics suggest Tuesday.
Total income in Novo Nordisk – which also brings diabetes and rare treatment of the disease – increased from 18% to 78.09 billion Danish crane compared to the expected 78.18 million Denmark.
Diabetes sales in the first quarter occurred at the level of 32.72 billion Danish crafers compared to forecasts of 31.5 billion Danish cranes.
In 2025, the company now sees sales growth by 13% to 21% at permanent courses, lower than 16% to 24% previously forecast in February. Profit growth in the operating forecast is projected by 16% to 24%, against 19% to 27% earlier.
CEO Novo Nordisk Lars Fruergaard Jørgensen attributed a reduced prognosis for competition from complex weight loss in the US
“In the first quarter of 2025, we reached 18% of sales growth and continued to expand the reach of our innovative GLP-1 treatments,” Joldensen said in a statement.
“However, we have reduced our full forecast due to the planned GLP-1 brand penetration, which affects the rapid extension of the US folding”
US pharmacies in the United States were allowed to make legal copies of Novo Wegovy and Diabetes Ozempic Ozempic according to drug deficits that supply nutrition and medicine management (FDA).
The FDA said in February that the deficit, giving sophisticated pharmacies until May 22 to stop the sale of drug copies. However Jørgensen reaffirmed that the company Pursuing companies Continuing illegally distributing such copy drugs.
Competition is heated
The results come against the background of the shoots of demand for the treatment of weight loss GLP-1 drug addicts, imitating the hormone called glucagon similar to peptide-1 to suppress appetite.
However, the company fought to shake the negative moods after a number Disappointing results of the trial For his next -generation drug candidate Cagrisema.
Novo Nordisk confirmed on Wednesday that it plans to apply for a regulatory approval of Cagrisema in the first quarter of 2026. Meanwhile, he appealed to the normative approval in the US oral version of the existing treatment of Semaglutid, which, he said, could be “the first verbal treatment of the GLP-1 for obesity.”
Competition is heated on the weight loss market, in that pharmaceutical firms, including Rosh. Astrazeneca and Abbvie All are now developing Potential new candidates.
Novo’s key opponent Eli Lily Thursday reported a decrease in waiting By 45% sales growth in the first quarterAlthough income from popular weight loss drugs came slightly lower than expected at lower drug prices. The American drug manufacturer has also reduced its full-fledged income recommendations due to allegations related to a recent cancer transaction, sending shares below.
